Methods of expressing proteins with disulfide bridges
View Patent ↗This invention relates to methods of expressing eukaryotic proteins in prokaryotic hosts, particularly eukaryotic proteins that require formation of disulfide bridges for biological activity. Various approaches are used including fusion to thioredoxin, cytoplasmic expression of disulfide isomerases, deficiencies in thioredoxin and/or glutathione reductases, deficiencies in proteases, and the like. The method is applicable to express monomeric and dimeric forms of the eukaryotic protein with biological activity such as monomeric and dimeric forms of a disintegrin or a disintegrin domain. Included are the vectors, host cells expressing the proteins, the expressed proteins and methods of using the proteins.
1. A method of treating a disease or condition in an individual by inhibiting in vivo platelet aggregation, cell growth, cell adhesion, metastasis, or neovascularization, said method comprising administering to the individual in need of such treatment an effective amount of a monomeric disintegrin or monomeric disintegrin domain comprising the amino acid sequence set forth in SEQ ID NO: 5.
2. The method of claim 1 wherein said monomeric disintegrin or monomeric disintegrin domain further comprises thioredoxin as an N-terminal segment and a eukaryotic protein as a C-terminal segment that requires formation of at least two intrachain or interchain disulfide bridges for biological activity and is in biologically active form.
3. The method of claim 2 wherein the thioredoxin has the sequence as set forth in SEQ ID NO: 1.
4. The method of claim 2 wherein the thioredoxin has the sequence as set forth in SEQ ID NO: 49 as the active site sequence.
5. The method of claim 2 wherein the thioredoxin has the sequence as set forth in SEQ ID NO: 48 as the active site sequence.
6. The method of claim 2 wherein cleavage site is located between the thioredoxin N-terminal segment and the eukaryotic protein C-terminal segment.
7. The method of claim 6 wherein the cleavage site is susceptible to proteolysis.
8. The method of claim 7 wherein the cleavage site is a TEV cleavage site having a sequence selected from the group consisting of SEQ ID NO: 53 or SEQ ID NO: 54.
9. The method of claim 6 wherein the cleavage site is susceptible to chemical cleavage.
10. The method of claim 6 wherein the cleavage site sequence has amino acid sequence DP.
11. The method of claim 2 wherein the monomeric disintegrin or monomeric disintegrin domain further comprises a peptide sequence which is a ligand for a receptor.
12. The method of claim 11 wherein the peptide sequence comprises a poly histidine sequence.
13. The method of claim 2 wherein the C-terminal sequence further comprises the amino acid sequence HKGPAT as set forth in SEQ ID NO: 47.
14. The method of claim 1 wherein the disease or condition is breast carcinoma.
15. The method of claim 1 wherein the monomeric disintegrin or monomeric disintegrin domain is encapsulated in liposomes.
16. The method of claim 15 wherein the liposomes comprise disteroylphosphatidylcholine, cholesterol and polyethylene glycol derivatized lipid.
17. The method of claim 1 wherein the monomeric disintegrin or monomeric disintegrin domain binds to one or more integrins selected from the group consisting of αllbβ3, αvβ3, αvβ5, and α5β1.
18. The method of claim 17 wherein the integrin is αllbβ3.